
    
      The drug being tested in this study is called pioglitazone. Pioglitazone is being tested to
      treat glycemic control in adults with inadequately controlled type 2 diabetes mellitus. This
      study will look at glycemic control in people who take triple oral therapy of metformin,
      sulfonylurea, and pioglitazone 15 mg.

      The study will enroll approximately 114 patients. All participants will be asked to take one
      pioglitazone tablet at the same time each day throughout the study as well as continuing
      their previous dose of metformin and sulfonylurea.

      This multi-center trial will be conducted in Korea. The overall time to participate in this
      study is up to 25 weeks. Participants will make 4 visits to the hospital or endocrinologist's
      office, and will be contacted by telephone 7 days after last dose of study drug for a
      follow-up assessment.
    
  